Acute Lymphoblastic Leukemia (ALL): The New Tools Shaping Tomorrow

With so many new advances in acute lymphoblastic leukemia (ALL), understanding today’s treatment landscape can give patients a clearer, more hopeful outlook.

In this episode, we speak with Marlise Luskin, MD of the Dana-Farber Cancer Institute, about what adults should know when facing a diagnosis of acute lymphoblastic leukemia. Dr. Luskin helps listeners understand how ALL develops, how subtypes are identified, and why genetics play an important role in guiding treatment. She discusses current therapies including chemotherapy, targeted agents and immunotherapies including CAR T-cell therapy, as well as how care teams monitor progress and manage side effects. While ALL is a complex disease, patients and caregivers will hear clear explanations, practical information, and meaningful reasons to feel hopeful about the advances shaping ALL care today.

CLICK HERE to participate in our episode survey.

Mentioned on this episode: 

• Acute lymphoblastic leukemia (ALL)
• Minimal/measurable residual disease (MRD) fact sheet
• Allogeneic stem cell transplantation
• Clinical Trial Support Center
• ALL Children and Teens booklet

Additional Blood Cancer United Support Resources: 

• Information Specialists 
• Financial support
• Online Chat
• Free Nutrition Consultations
• Free telephone/web patient programs 
• Free booklets 
• Support groups 
• Caregiver support 
• Caregiver Workbook
• Young Adult Resources
• Survivorship Workbook
• Advocacy and Public Policy
• Patient Community
• Mental Health Resources

Episode supported by Syndax Pharmaceuticals Inc.

The post Acute Lymphoblastic Leukemia (ALL): The New Tools Shaping Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.